Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for Long-term Remission in Newly Diagnosed Type 2 Diabetes
ChiCTR-IPR-16009666Phase 4Recruiting
- Sponsor
- Liaocheng City People's Hospital
- Start
- Dec 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Liaocheng City People's Hospital. Primary endpoints: Fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (2hPG) and 4 more. Started Dec 2016; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IPR-16009666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009666.